Ticker

PURCHASE, N. Y. , July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B.

PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D.,…

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and…

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.